Larimar Therapeutics (LRMR) Interest Coverage Ratio (2014 - 2020)
Larimar Therapeutics' (LRMR) quarterly Interest Coverage Ratio came in at 22.17 in Q1 2020, up 16.5% on a YoY basis from 19.03 in Q2 2019, and down 30.34% quarter-over-quarter from 17.01 in Q4 2019.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Interest Coverage Ratio (2014 - 2020) Analysis & Trends
Larimar Therapeutics (LRMR) has reported Interest Coverage Ratio for 7 consecutive years, with 22.17 the latest figure, recorded in Q1 2020.
- For the quarter ending Q1 2020, Interest Coverage Ratio rose 16.5% year-over-year to 22.17; the trailing twelve-month figure through Mar 2020 stood at 16.06 (up 46.92% YoY), and the FY2019 full-year result was 13.14, up 59.18% from the prior year.
- Interest Coverage Ratio fell to 22.17 in Q1 2020 per LRMR's latest filing, from 17.01 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 7.75 in Q2 2019 and bottomed at 1669.75 in Q4 2017.
- Historically, Interest Coverage Ratio has averaged 187.26 across 5 years, with a median of 34.28 in 2018.
- The sharpest annual moves came in 2017 and 2018: Interest Coverage Ratio slumped 1446.21% in 2017, then soared 98.24% in 2018.
- Over 5 years, Interest Coverage Ratio stood at 107.99 in 2016, then plunged by 1446.21% to 1669.75 in 2017, then surged by 98.24% to 29.44 in 2018, then surged by 42.22% to 17.01 in 2019, then sank by 30.34% to 22.17 in 2020.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 22.17, 17.01, and 20.25 for Q1 2020, Q4 2019, and Q3 2019 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | -493.00 |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -0.08 |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | -22.17 |
| Dec 31, 2019 | -17.01 |
| Sep 30, 2019 | -20.25 |
| Jun 30, 2019 | -7.75 |
| Mar 31, 2019 | -26.55 |
| Dec 31, 2018 | -29.44 |
| Sep 30, 2018 | -31.93 |
| Jun 30, 2018 | -33.39 |
| Mar 31, 2018 | -34.28 |
| Dec 31, 2017 | -1,669.75 |
| Sep 30, 2017 | -414.19 |
| Jun 30, 2017 | -255.40 |
| Mar 31, 2017 | -181.71 |
| Dec 31, 2016 | -107.99 |
| Sep 30, 2016 | -112.36 |
| Jun 30, 2016 | -107.59 |
| Mar 31, 2016 | -111.61 |
| Dec 31, 2015 | -129.14 |
| Sep 30, 2015 | -98.59 |
| Jun 30, 2015 | -82.68 |